This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
EAU 2018
EAU 2018 Bladder Cancer
EAU 2018
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testis and Penile Cancer
Endourology
Press
Conferences
Viewing 1-20 of 11696 articles
IBCN 2024: Mechanisms of Resistance to Antibody Drug Conjugates
IBCN 2024: Systematic Evaluation of Differentially Expressed Genes Associated with Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
IBCN 2024: Quantifying Intra-tumoral Molecular Subtype Heterogeneity in MIBC from Histological Slides using a deep learning approach in the VESPER Trial
IBCN 2024: Oncolytic Virotherapy Expressing a Novel TLR Agonist and IL-15 for the Treatment of NMIBC
IBCN 2024: Spatial Proteomics and Transcriptomics Reveal an Altered Immune Cell Landscape in Bladder Cancer Patients Unresponsive to BCG Treatment
IBCN 2024: Molecular Subtypes and Outcomes in the VESPER Trial
IBCN 2024: Molecular Subtyping in 2024: The LUMBER-NAC Trial
IBCN 2024: GUSTO Trial
IBCN 2024: ADC Toxicity, Management and Clinical Trial Updates
IBCN 2024: Benefit of Whole-Pelvis Radiation for Patients with Muscle Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis
IBCN 2024: Influence of Immortal Time Bias and Conditional Survival on the Comparison of Radical Cystectomy Versus Trimodality Therapy for Muscle Invasive Bladder Cancer
IBCN 2024: Using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Preliminary Analysis from the BOND-003 Trial
IBCN 2024: EG-70 (Detalimogene Voraplasmid), a Novel, Non-Viral, Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS: Preclinical Characterization and Translation into the Clinic
IBCN 2024: Augmented Cystoscopy with Deep Learning
IBCN 2024: The Value of mpMRI to Assist in Decision Making in Muscle Invasive Bladder Cancer
IBCN 2024: TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Patients with BCG Unresponsive High-Risk NMIBC: Results from SunRISe-1
IBCN 2024: TAR-200 Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients With Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Platinum-Based Chemotherapy: Interim Analysis of SunRISe-4
IBCN 2024: AI in Bladder Cancer: The Good, the Bad, and the Ugly
IBCN 2024: A Randomized Phase II Trial Comparing Single Dose Perioperative Instillation of Intravesical Gemcitabine Versus Mitomycin-C Following Complete Resection of Non-Muscle Invasive Bladder Cancer: Evaluation of Efficacy and Tolerance
IBCN 2024: AI-Enabled Bladder Cancer Grading: Externally Validating Quantitative Nuclear Features and Demonstrating Their Potential to Better Predict Time to Recurrence
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
